Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Estrogen response in luminal breast cancer.

Rangel LB, Huang TH.

Oncotarget. 2013 Oct;4(10):1548-9. No abstract available.

2.

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics.

Groenendijk FH, Zwart W, Floore A, Akbari S, Bernards R.

Breast Cancer Res Treat. 2013 Aug;140(3):475-84. doi: 10.1007/s10549-013-2648-1. Epub 2013 Aug 4.

3.

Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.

Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA.

Breast Cancer Res. 2011 Jan 28;13(1):R11. doi: 10.1186/bcr2819.

4.

Interaction between estrogen receptor alpha and insulin/IGF signaling in breast cancer.

Lanzino M, Morelli C, Garofalo C, Panno ML, Mauro L, Andò S, Sisci D.

Curr Cancer Drug Targets. 2008 Nov;8(7):597-610. Review.

PMID:
18991569
5.

miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.

Endo Y, Toyama T, Takahashi S, Yoshimoto N, Iwasa M, Asano T, Fujii Y, Yamashita H.

Endocr Relat Cancer. 2013 Feb 18;20(1):91-102. doi: 10.1530/ERC-12-0207. Print 2013 Feb.

6.

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?

Lakhani SR, Khanna KK, Chenevix-Trench G.

Breast Cancer Res. 2010;12(2):104. doi: 10.1186/bcr2483. Epub 2010 Mar 19.

7.

Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression.

Maity B, Stewart A, O'Malley Y, Askeland RW, Sugg SL, Fisher RA.

Carcinogenesis. 2013 Aug;34(8):1747-55. doi: 10.1093/carcin/bgt128. Epub 2013 Apr 18.

8.

Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.

Tolhurst RS, Thomas RS, Kyle FJ, Patel H, Periyasamy M, Photiou A, Thiruchelvam PT, Lai CF, Al-Sabbagh M, Fisher RA, Barry S, Crnogorac-Jurcevic T, Martin LA, Dowsett M, Charles Coombes R, Kamalati T, Ali S, Buluwela L.

Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.

PMID:
20730598
9.

Effects of estriol on growth, gene expression and estrogen response element activation in human breast cancer cell lines.

Diller M, Schüler S, Buchholz S, Lattrich C, Treeck O, Ortmann O.

Maturitas. 2014 Apr;77(4):336-43. doi: 10.1016/j.maturitas.2014.01.004. Epub 2014 Jan 23.

PMID:
24529907
10.

Analysis of the ERalpha germline PvuII marker in breast cancer risk.

González-Mancha R, Galán JJ, Crespo C, Iglesias Pérez L, González-Perez A, Morón FJ, Moreno Nogueira JA, Real LM, Pascual MH, Ruiz A, Royo JL.

Med Sci Monit. 2008 Mar;14(3):CR136-43.

PMID:
18301357
11.

The relevance of phosphorylated forms of estrogen receptor in human breast cancer in vivo.

Murphy LC, Skliris GP, Rowan BG, Al-Dhaheri M, Williams C, Penner C, Troup S, Begic S, Parisien M, Watson PH.

J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):90-5. doi: 10.1016/j.jsbmb.2009.01.017. Epub 2009 Feb 6. Review.

PMID:
19429437
13.

Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.

Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.

Breast Cancer Res Treat. 2010 Jul;122(2):395-407. doi: 10.1007/s10549-009-0581-0. Epub 2009 Oct 22.

PMID:
19847644
14.

The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.

Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE.

Mol Cancer. 2010 Jun 15;9:150. doi: 10.1186/1476-4598-9-150.

15.

The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.

Privette Vinnedge LM, Ho SM, Wikenheiser-Brokamp KA, Wells SI.

PLoS One. 2012;7(10):e46985. doi: 10.1371/journal.pone.0046985. Epub 2012 Oct 10.

16.

Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.

Allred DC.

Mod Pathol. 2010 May;23 Suppl 2:S52-9. doi: 10.1038/modpathol.2010.55. Review.

17.

Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status.

Garcia-Closas M, Troester MA, Qi Y, Langerød A, Yeager M, Lissowska J, Brinton L, Welch R, Peplonska B, Gerhard DS, Gram IT, Kristensen V, Børresen-Dale AL, Chanock S, Perou CM.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2269-75.

18.

Human glutathione S-transferase P1-1 functions as an estrogen receptor α signaling modulator.

Liu X, An BH, Kim MJ, Park JH, Kang YS, Chang M.

Biochem Biophys Res Commun. 2014 Sep 26;452(3):840-4. doi: 10.1016/j.bbrc.2014.09.017. Epub 2014 Sep 16.

PMID:
25218501
19.

The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells.

Jiang Z, Guo J, Shen J, Jin M, Xie S, Wang L.

J Exp Clin Cancer Res. 2012 May 3;31:42. doi: 10.1186/1756-9966-31-42.

20.

Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.

Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.

Breast Cancer Res. 2005;7(5):R753-64. Epub 2005 Jul 27.

Supplemental Content

Support Center